PARI Devices used in SHIP Study of Hypertonic Saline in Preschoolers with Cystic Fibrosis
MIDLOTHIAN, Va., Nov. 29, 2018 /PRNewswire/ -- A recent study in preschoolers with cystic fibrosis (CF) conducted by Cystic Fibrosis Foundation Therapeutics used PARI's LC Sprint Jr. nebulizer, Vios PRO compressor, and PARI's 7% hypertonic saline. The study called SHIP (Saline Hypertonic in Preschoolers) showed that PARI's 7% hypertonic saline inhaled twice daily using the PARI LC Sprint Jr. and the Vios PRO compressor resulted in a sustained and significant improvement in a lung function test called the lung clearance index over 48 weeks.
"PARI was the first company in the USA to receive clearance to market by the FDA for hypertonic saline 7% inhalation solution in unit-dose form, which includes production under Good Manufacturing Practice (GMP) conditions to ensure consistency. We are pleased that researchers chose PARI's aerosol delivery devices and hypertonic saline for the SHIP Study and the positive results show that treatment with hypertonic saline can benefit preschoolers with CF" said Lisa Cambridge, director of medical science at PARI.
The results from the SHIP study were presented last month at the North American Cystic Fibrosis Conference in Denver, CO. The study compared nebulized 7% hypertonic saline to 0.9% isotonic saline in children 3-5 years of age with CF. The study found that nebulized 7% hypertonic saline after pre-treatment with albuterol significantly improved the lung clearance index over 48 weeks compared to 0.9% saline (the control agent).
Hypertonic saline is commonly used by people with CF to help thin mucus in the lungs and promote airway clearance.
About Cystic Fibrosis Cystic fibrosis, a progressive, genetic disease affecting 30,000 people in the US; it is caused by a genetic mutation that results in poorly hydrated, thickened mucus secretions in the lungs.
About PARI Respiratory Equipment, Inc. PARI is a leading, worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, cystic fibrosis, RSV, VAP, and HAP. PARI's worldwide mission is to improve the lives of those affected by respiratory diseases and those who provide care for them. This is reflected in our comprehensive portfolio of innovative products. PARI is considered the gold standard in aerosol delivery for nebulizer therapies. Featured products include Kitabis Pak (co-packaging of tobramycin inhalation solution and PARI LC PLUS Nebulizer), PARI LC PLUS and LC Sprint Reusable Nebulizers, Vortex® Holding Chamber, and the drug-specific eFlow Technology platform.
